Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.


Autoria(s): Lugthart S.; Gröschel S.; Beverloo H.B.; Kayser S.; Valk P.J.; van Zelderen-Bhola S.L.; Jan Ossenkoppele G.; Vellenga E.; van den Berg-de Ruiter E.; Schanz U.; Verhoef G.; Vandenberghe P.; Ferrant A.; Köhne C.H.; Pfreundschuh M.; Horst H.A.; Koller E.; von Lilienfeld-Toal M.; Bentz M.; Ganser A.; Schlegelberger B.; Jotterand M.; Krauter J.; Pabst T.; Theobald M.; Schlenk R.F.; Delwel R.; Döhner K.; Löwenberg B.; Döhner H.
Data(s)

2010

Resumo

PURPOSE: Acute myeloid leukemia (AML) with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) [inv(3)/t(3;3)] is recognized as a distinctive entity in the WHO classification. Risk assignment and clinical and genetic characterization of AML with chromosome 3q abnormalities other than inv(3)/t(3;3) remain largely unresolved. PATIENTS AND METHODS: Cytogenetics, molecular genetics, therapy response, and outcome analysis were performed in 6,515 newly diagnosed adult AML patients. Patients were treated on Dutch-Belgian Hemato-Oncology Cooperative Group/Swiss Group for Clinical Cancer Research (HOVON/SAKK; n = 3,501) and German-Austrian Acute Myeloid Leukemia Study Group (AMLSG; n = 3,014) protocols. EVI1 and MDS1/EVI1 expression was determined by real-time quantitative polymerase chain reaction. RESULTS: 3q abnormalities were detected in 4.4% of AML patients (288 of 6,515). Four distinct groups were defined: A: inv(3)/t(3;3), 32%; B: balanced t(3q26), 18%; C: balanced t(3q21), 7%; and D: other 3q abnormalities, 43%. Monosomy 7 was the most common additional aberration in groups (A), 66%; (B), 31%; and (D), 37%. N-RAS mutations and dissociate EVI1 versus MDS1/EVI1 overexpression were associated with inv(3)/t(3;3). Patients with inv(3)/t(3;3) and balanced t(3q21) at diagnosis presented with higher WBC and platelet counts. In multivariable analysis, only inv(3)/t(3;3), but not t(3q26) and t(3q21), predicted reduced relapse-free survival (hazard ratio [HR], 1.99; P < .001) and overall survival (HR, 1.4; P = .006). This adverse prognostic impact of inv(3)/t(3;3) was enhanced by additional monosomy 7. Group D 3q aberrant AML also had a poor outcome related to the coexistence of complex and/or monosomal karyotypes and cryptic inv(3)/t(3;3). CONCLUSION: Various categories of 3q abnormalities in AML can be distinguished according to their clinical, hematologic, and genetic features. AML with inv(3)/t(3;3) represents a distinctive subgroup with unfavorable prognosis.

Identificador

http://serval.unil.ch/?id=serval:BIB_906C954AD411

isbn:1527-7755[electronic], 0732-183X[linking]

pmid:20660833

doi:10.1200/JCO.2010.29.2771

isiid:000281129700015

Idioma(s)

en

Fonte

Journal of Clinical Oncology, vol. 28, no. 24, pp. 3890-3898

Palavras-Chave #Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Cell Adhesion Molecules/metabolism; Chromosome Aberrations; Chromosome Inversion; Chromosomes, Human, Pair 3; Clinical Trials as Topic; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meiers Estimate; Karyotyping; Leukemia, Myeloid, Acute/genetics; Leukemia, Myeloid, Acute/metabolism; Male; Middle Aged; Monosomy; Multivariate Analysis; Mutation; Neoplasm Proteins/metabolism; Odds Ratio; Predictive Value of Tests; Prognosis; Remission Induction; Translocation, Genetic; Treatment Outcome; Tumor Markers, Biological/metabolism
Tipo

info:eu-repo/semantics/article

article